Abstract 1949P
Background
Conventional use of doxorubicin as a single-agent or in combinations with other drugs in the treatment of uterine sarcomas is associated with dose-limiting toxicities. Doxorubicin plus trabectedin was shown to increase progression-free survival (PFS) at the price of higher toxicity. PLD plus trabectedin revealed to be feasible in larger phase 2 and 3 randomised studies in ovarian cancer. We hypothesise that the therapeutic index of trabectedin plus PLD could be superior to the combination with doxorubicin because of a more favourable toxicity profile.
Methods
In this retrospective single-arm study the clinical outcome was analysed in 21 patients with uterine sarcomas treated with PLD 30 mg/m2 plus trabectedin 1.1 mg/m2 every three weeks between January 2000 and April 2023 at the University Hospital in Innsbruck. Response evaluation was done every 3 cycles and every 3 months during the post-treatment follow-up. Toxicity was evaluated according to the National Cancer Institute-Common Terminology criteria, on a total of 148 administered cycles in 33 patients.
Results
In 66% of patients PLD plus trabectedin was given as first-line treatment, in 19% and 14% as second and third-line treatment, respectively. After 6 months one patient (4.8%) achieved complete remission (CR), four others (19%) showed a partial remission (PR), resulting in an objective response rate (ORR) of 24%. Four patients (19%) showing stable disease (SD), resulting in a clinical benefit rate (= ORR + SD) of 43%; progression was recorded in 12 patients (57%). Median PFS was 6.0 months (SD: ±21 months), while median overall survival was 26 months (SD: ±32 months). A median of 4 (range: 1-11) cycles per patient were given. Regarding ≥ grade 3 toxicity, thrombocytopenia was recorded in 9%, anaemia in 12% and neutropenia in 36% of patients. Febrile neutropenia was present in 7 patients (21%). Haematologic toxicity was the most frequent reason for dose delays (25 events) and dose reductions in eight cases.
Conclusions
Compared to conventional doxorubicin plus trabectedin, the herein investigated combination shows limited but similar anti-tumor efficacy in metastatic uterine sarcomas, but exhibits a more favourable toxicity profile.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1830P - CBP-1018, a bi-ligand-drug conjugate treated in patients with advanced solid tumors: A phase I, multi-center, open-label, dose-escalation and dose expansion study
Presenter: Kaiwen Li
Session: Poster session 15
1831P - Dissecting the meaning of obesity in metastatic castration resistant prostate cancer: Size or metabolism?
Presenter: Lisa Horvath
Session: Poster session 15
1832P - Centralized screening for homologous recombination repair (HRR) genes in metastatic castration-resistant prostate cancer (mCRPC): A feasibility study from a multicenter Spanish cohort
Presenter: Javier Freire
Session: Poster session 15
1833P - Concurrent high-dose IV Vitamin C (IVC) and docetaxel for metastatic castrate-resistant prostate cancer (mCRPC): A randomized, placebo-controlled, double-blind phase II trial
Presenter: Channing Paller
Session: Poster session 15
1834P - Exposure-efficacy analyses of talazoparib in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) in the TALAPRO-2 trial
Presenter: Arun Azad
Session: Poster session 15
1835P - A prospective study to determine the prevalence of DNA repair defects in patients (pts) with advanced prostate cancer (PC)
Presenter: Shahneen Sandhu
Session: Poster session 15
1836P - Blood based biomarkers identify metastatic castration-resistant prostate cancer (mCRPC) with the greatest benefit from continuing enzalutamide (ENZ) beyond progression in combination with docetaxel (Doc): A pre-specified biomarker study of the phase IIIb PRESIDE trial
Presenter: Maria Ruiz Vico
Session: Poster session 15
1837P - Assessing PSA
Presenter: Susan Halabi
Session: Poster session 15
1839P - Circulating tumor DNA (ctDNA) low pass whole genome sequencing (lpWGS) studies identify genomic alterations associating with taxane outcomes in prospective phase III taxane trials for metastatic castration resistant prostate cancer (mCRPC) sufferers
Presenter: George Seed
Session: Poster session 15